Clinical Trial Update: An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) [Phase 2]

View source ↗

Summary

An open-label, ascending, repeated-dose Phase 2 trial evaluating sarilumab in children and adolescents with polyarticular-course juvenile idiopathic arthritis h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Idiopathic Arthritis

Drugs mentioned

• Sarilumab (sarilumab)

Snippet

Sponsor: Sanofi | Conditions: Juvenile Idiopathic Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2024-10-15